Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(14 sites)

United States

Arkansas Children's Hospital, Little Rock, Arkansas

Luskin Orthopaedic Institute For Children, Los Angeles, California

UC Davis Medical Center, Sacramento, California

University of California San Francisco, San Francisco, California

Emory University Hospital, Atlanta, Georgia

Children's Healthcare of Atlanta, Atlanta, Georgia

University of Minnesota, Minneapolis, Minnesota

Science 37, Inc. (Virtual Clinical MetaSite), Morrisville, North Carolina

Hemophilia Center of Western PA, Pittsburgh, Pennsylvania

UT Southwestern Children's Hospital, Dallas, Texas

Washington Center for Bleeding Disorders, Seattle, Washington

Georgia

K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი), Tbilisi

Germany

Frankfurt University Hospital (Universitätsmedizin Frankfurt), Frankfurt

South Africa

Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist, Johannesburg